An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer

PURPOSE: GDC-0927 is a novel, potent, nonsteroidal, orally bioavailable, selective estrogen receptor (ER) degrader that induces tumor regression in ER(+) breast cancer xenograft models. PATIENTS AND METHODS: This phase I dose-escalation multicenter study enrolled postmenopausal women with ER(+)/HER2...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandarlapaty, Sarat, Dickler, Maura N., Perez Fidalgo, Jose Alejandro, Villanueva-Vázquez, Rafael, Giltnane, Jennifer, Gates, Mary, Chang, Ching-Wei, Cheeti, Sravanthi, Fredrickson, Jill, Wang, Xiaojing, Collier, Ann, Moore, Heather M., Metcalfe, Ciara, Lauchle, Jennifer, Humke, Eric W., Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390885/
https://www.ncbi.nlm.nih.gov/pubmed/37261814
http://dx.doi.org/10.1158/1078-0432.CCR-23-0011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390885/
https://www.ncbi.nlm.nih.gov/pubmed/37261814
http://dx.doi.org/10.1158/1078-0432.CCR-23-0011

Ejemplares similares